Ivermectin Cream for Rosacea

The approved indication is one line long. Ivermectin cream 1% is indicated for the treatment of inflammatory lesions of rosacea. Inflammatory lesions means papules and pustules: the raised bumps and the small pus-topped spots. It does not mean the background flush, the persistent red cheeks, or the fine threadlike vessels that so often sit next to them.

That one distinction decides whether this cream will do anything for your face. Most pages on the subject walk straight past it.

Both registration trials enrolled a narrow group. Across 1,371 adults, 79% were graded moderate and 21% severe on a five-point Investigator Global Assessment at baseline, all of them with papulopustular disease. A 2018 systematic review states the boundary plainly: ivermectin has only been tested in moderate-to-severe papulopustular rosacea. If your rosacea is mostly color with few or no bumps, you sit outside the population every trial studied, and the honest answer is that this evidence does not reach you.

One more thing to clear away first. Oral ivermectin is a different product carrying a different label: the tablets are approved for intestinal strongyloidiasis and onchocerciasis, two parasitic infections, at single weight-based doses. The cream is a topical dermatology drug for the face, and its own label says it is not for oral, ophthalmic, or intravaginal use. The public argument about ivermectin was about swallowing tablets for a viral illness. It has no bearing on this cream.

Ivermectin is an antiparasitic, and two things happen when it goes on rosacea skin. It kills Demodex folliculorum, the mite that lives in facial follicles, and it appears to blunt the inflammatory cascade in its own right. The association behind that first action is strong: a meta-analysis of 48 case-control studies covering 28,527 enrolled across ten countries found a pooled odds ratio of 7.57, with a 95% confidence interval of 5.39 to 10.62. That number is the reason an anti-mite drug ended up as a rosacea treatment at all.

A strong association is not an established mechanism, and the label makes no pretense otherwise. Section 12.1 reads, in full, that the mechanism of action of the cream in treating rosacea lesions is unknown. A 2020 review of the Demodex hypothesis lands in the same place: the mite is beginning to be accepted as one of the triggers of the inflammatory cascade, and the approach needs confirmation by prospective controlled trials with long-term follow-up. The 2018 review agrees, calling for more research to establish the clinical benefit of the acaricidal action. Believe the effect; hold the story loosely.

Two identically designed, randomized, double-blind, vehicle-controlled trials treated 1,371 adults once daily for 12 weeks. On the co-primary endpoint of clear or almost clear skin, 38.4% and 40.1% succeeded on ivermectin against 11.6% and 18.8% on vehicle cream, while inflammatory lesion counts fell by a mean of 20.5 and 22.2 lesions, or 64.9% and 65.7%, against 41.6% and 43.4%.

Look hard at that vehicle column. A plain moisturizing base with no drug in it cut lesions by more than 40%, which is worth remembering next to any before-and-after photograph.

The gap opened early and held. Ivermectin beat vehicle on both co-primary endpoints starting from four weeks of treatment in both studies. The journal report of those same two trials quotes a larger effect, 76.0% and 75.0% lesion reduction against 50.0% in both vehicle groups, because it derives its percentage differently from the label's absolute-change analysis. Where two figures for one trial disagree, the label's is the one that went through FDA review, so that is the one quoted above.

Ivermectin and metronidazole were tested against each other in one trial rather than compared across separate ones. A phase 3 investigator-blinded trial randomized 962 adults with moderate to severe papulopustular rosacea to ivermectin once daily or metronidazole 0.75% cream twice daily for 16 weeks. Lesions fell 83.0% against 73.7% (P<0.001), a difference visible as early as week 3, and 84.9% against 75.4% were rated clear or almost clear. In the severe subgroup of 161 who started at the top of the scale, the gap widened to 82.5% against 63.0% clear or almost clear at week 16 (P=0.005).

Against azelaic acid the evidence is indirect. A Bayesian network meta-analysis drawing on 19 comparable trials put once-daily ivermectin ahead of azelaic acid 15% gel twice daily, relative risk 1.25 with a 95% credible interval of 1.14 to 1.37 at 12 weeks, and 8.04 fewer inflammatory lesions. Set against that, a GRADE assessment of 152 studies covering 20,944 enrolled rates topical azelaic acid and topical ivermectin both as high-certainty evidence for reducing papules and pustules, with topical metronidazole at moderate certainty. Ranking first is not the same as being the only defensible choice.

Rosacea returns, and the extension study is where you learn how fast. Treatment stopped in 399 adults cleared on ivermectin and 365 cleared on metronidazole, who were then followed every four weeks for up to 36 weeks. Median time to first relapse was 115 days against 85 days, and the median count of treatment-free days was 196 against 169.5 (P=0.026).

Thirty extra days is a genuine, measured advantage. It is also the entire advantage. Nothing in that design produced remission.

The relapse totals in the same extension were 62.7% on ivermectin and 68.4% on metronidazole by the end of the follow-up. A systematic review turned that into a number needed to treat of 17.5 at week 36 to prevent one relapse, against 10.5 at 12 weeks for the clearing effect, and concluded that about two-thirds relapsed on either drug after stopping. If killing mites were the durable advantage the mechanism story suggests, that relapse gap should be much wider than six percentage points.

The instruction is unusually short. Apply to the affected areas of the face once daily, using a pea-size amount for each affected area (forehead, chin, nose, each cheek), spread as a thin layer, avoiding the eyes and lips. A face with bumps across both cheeks and the chin therefore takes three peas rather than one, which is where many courses quietly go wrong. The label sets no titration schedule, requires no bloodwork before starting, and lists no contraindications at all.

Twelve weeks is the number to hold. The registration trials read out their co-primary endpoints at week 12 and the head-to-head against metronidazole ran to week 16. Improvement is measurable well before that, from week 4 against vehicle and week 3 against metronidazole, but the full effect is a season away rather than a fortnight. The drug itself is slow to leave: the apparent terminal half-life averaged 6.5 days after 28 days of once-daily use, and plasma levels showed no accumulation across 52 weeks.

Controlled-trial tolerability is genuinely good. The label reports skin burning sensation and skin irritation at 1% or less among 2,047 treated once daily, 519 of them for about a year. The head-to-head trial recorded better local tolerability on ivermectin than on metronidazole, and the registration trials found fewer dermatologic adverse events and more faces free of dryness and itching than on vehicle. Contact dermatitis and allergic dermatitis appear only in postmarketing reports, which carry no usable frequency.

The early flare is real, but it sits far lower on the evidence ladder than those trial numbers, and it matters because it is what ends courses early. In a retrospective series of 39 with persistent erythema and high mite density, three of the seventeen started on ivermectin alone dropped out because of an early ivermectin-induced local flare. A 2022 report proposes the mechanism in its title, describing a transient flare of rosacea as a host reaction to killed Demodex mites, preventable by short-term topical corticosteroid. One series and one report do not make a rate. Take a worsening back to your prescriber rather than quitting on your own.

Different features of rosacea take different drugs, which is why the phenotype question is not academic. Brimonidine 0.33% gel is approved for persistent facial erythema; across two four-week trials in 553 adults, 31% and 25% hit the two-grade composite success mark three hours after dosing against 11% and 9% on vehicle. Oxymetazoline 1% cream carries the same indication and was studied in 885 adults over 29 days. Both act for hours at a time and neither touches lesion counts. For erythema with mainly telangiectasia, the GRADE review found only low-to-moderate-certainty evidence for laser and intense pulsed light.

Eyes and nose are separate problems again. For ocular rosacea that same review found moderate-certainty evidence for oral omega-3 fatty acids and low-certainty evidence for ciclosporin ophthalmic emulsion and doxycycline. Even the oral anti-inflammatory rosacea drug states the boundary on its own label: doxycycline 40 mg modified release has not been evaluated for the erythematous, telangiectatic, or ocular components of rosacea. Phymatous thickening of the nose is tissue remodelling and no cream reverses it. Global consensus recommends combination therapy where several features present at once.

Ivermectin is the expensive topical in this category and the spread is not subtle. In the federal National Average Drug Acquisition Cost file published on 2 September 2026, generic ivermectin 1% cream is listed at $2.96753 per gram, generic azelaic acid 15% gel at $0.43454 per gram, and generic metronidazole 0.75% cream at $0.26843 per gram. At those rates a 30 gram tube of ivermectin cream works out near $89, while a 45 gram tube of metronidazole cream lands close to $12. That is an elevenfold gap for a nine-point difference in lesion reduction. Read those figures for what they are. NADAC is what pharmacies pay to buy a drug, not what a pharmacy or a telehealth service charges you, and the two are different numbers.

We publish no single monthly price for this treatment because we have not verified one against a live source. The same file prices the other prescription routes very differently: brimonidine 0.33% gel, the topical aimed at redness rather than bumps, at $13.83956 per gram, and generic doxycycline 40 mg modified-release capsules, the oral anti-inflammatory option, at $4.29493 each. Thirty days of that doxycycline capsule is about $129 of acquisition cost, so the oral route is not the cheap one here. Generic ivermectin cream does exist, with its own label published on DailyMed alongside the brand.

Rosacea is diagnosed by looking at a face, so it maps onto remote care better than most conditions do. There is no required blood test, and the label sets no monitoring schedule. Whether ivermectin cream suits you is a prescribing judgment a licensed clinician makes, and it turns on the same phenotype question this page opened with: whether your skin is producing papules and pustules, or mainly flushing and fixed color. Clear photographs in even daylight, taken without makeup, are the input that judgment runs on. Nothing on this page is medical advice.

Judge a service on what it does after the prescription is written. Global consensus sets complete clearance rather than partial improvement as the treatment objective, so a plan for week 12 matters: whether someone reviews your photographs again, whether an oral option is on the table, and who addresses the erythema if the bumps clear and the redness stays. Adding doxycycline 40 mg modified release to ivermectin in 273 adults with severe rosacea lifted lesion reduction from 73.6% to 80.3% (P=.032) and complete clearing of lesions from 7.2% to 17.8%.